All about COVID-19

Coronavirus | Vaccine was rapidly synthesised as novel coronavirus sequence was available, says virologist Gagandeep Kang

Gagandeep Kang   | Photo Credit: Special arrangement

Just over three months after the genome sequence of the novel coronavirus (SARS-CoV-2) was shared by Chinese researchers, an messenger-RNA (mRNA) vaccine is being tested at Seattle in a Phase-1 clinical trial on 45 healthy volunteers between the ages of 18 to 55 years over a period of approximately six weeks.

The trial began on March 16 at the Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants.

Coronavirus | The Hindu brings out e-book on essential COVID-19 information

The vaccine (mRNA-1273) was developed by National Institute of Allergy and Infectious Diseases (NIAID), U.S., scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial.

Virologist Gagandeep Kang, who is the executive director of the Translational Health Science and Technology Institute (THSTI), Faridabad, in an email to The Hindu explains how the mRNA vaccine is developed and how it has become possible to get the vaccine ready for testing so quickly.

What makes the use of messenger-RNA (mRNA) for the vaccine different from the conventional vaccines and how does it work?

Most of the vaccines we know are based on a whole organism (bacteria or virus, living or dead) or a part of an organism. Usually these organisms cause disease, but to make vaccines, the organism are manipulated by heat, chemical or other biological approaches to ensure that their pathogenicity has been removed. These vaccines, when given to a person, act like an infection, but without producing disease. The parts of the organism which are recognised by the immune response are called antigens, and when they are recognised, an immune response is made, as either antibodies or activated immune cells that protect from disease when the same infection is seen again.

Unlike a usual vaccine, RNA vaccines work by the introduction of an mRNA sequence into the host’s cells. This mRNA codes for a disease-specific antigen. Once inside a cell, the mRNA instructs the cell to produce the antigen, which is recognised by the immune system which makes an antibody or cellular response.

Currently, two forms of mRNA vaccines are been widely developed against multiple pathogens: conventional mRNA vaccines and self-amplifying mRNA vaccines, which are derived from positive strand RNA viruses.

How has it become possible to develop an mRNA vaccine in just about three months? Is it necessary to have the virus to develop the vaccine?

In part, reseachers were able to quickly develop mRNA-1273 because of prior studies of related coronaviruses that cause SARS and MERS.

We have incredible genome sequencing capacity now, and got the SARS-CoV-2 sequence in early January 2020. Since all you need for the mRNA vaccine is the sequence of the pathogen, a vaccine could be rapidly synthesised in the laboratory.

Coronavirus | Testing is the easiest thing to do, says Gagandeep Kang

The mRNA can be made synthetically by in vitro transcription or reading of a plasmid DNA template, with a recombinant RNA polymerase. A cap and tail are attached to from a mature mRNA sequence.

No, the virus is not required, but the genome sequence [of the virus] is needed. The messenger RNAs are produced synthetically and this is what makes the technology rapid and reproducible.

Since a particular protein (spike protein) found on the virus is what binds to receptors found on human cells and then infect them, will the vaccine use mRNAs produced for this protein?

The first vaccine to enter human trials is Moderna’s mRNA-1273. This is a novel lipid nanoparticle-encapsulated mRNA vaccine that codes for the full-length prefusion stabilised spike (S) protein.

How do vaccine developers know which mRNAs of the spike protein are produced? How do they select the correct ones to be included in the vaccine?

The gene sequences of the proteins of coronaviruses are known. Even with a novel virus, it is possible to figure out which sequence codes for which protein. Only one mRNA is included and it is selected based on sequence matching.

Also read | Russia starts testing coronavirus vaccine prototypes on animals

Are the mRNAs used in the vaccine packed in some protective material or used bare?

In the case of Moderna, the mRNA is stabilised so that is protected from enzymes that might break it down.

Has this vaccine already been tested in animals for safety or is it tested on human volunteers bypassing animal trials? How ethical is this?

The US FDA has approved studies to proceed in parallel so human studies are also being done with the same product. The mRNA platform technology by which the vaccine was made has already been used safely in 1,700 volunteers for other mRNA vaccines. So the FDA will have considered that in its decision. There are always worries about ethics when testing in emergencies, because safety should be paramount for vaccines, but there is, so far, no safety signal [adverse effects] from the Moderna mRNA platform.

Coronavirus | China gives go-ahead for human trials of COVID-19 vaccine

With regard to the parallel studies in animals also, one unusual aspect of the mRNA-1273 vaccine is that although other formulations of similar vaccines have been tested on animals, this particular vaccine construct has not been evaluated in the appropriate animal model which is a transgenic mouse expressing the ACE2 receptor. Tal Zaks, Chief Medical Officer of Moderna was quoted in STAT, a news outlet, as saying: “I don’t think proving this in an animal model is on the critical path to getting this to a clinical trial,” He also pointed out that National Institute of Health scientists are “working on nonclinical research in parallel.”

Has there been any instance before when an mRNA vaccine has been tested on humans?

Many candidate vaccines have been produced using this technology and are in various phases of testing. Currently, there are over 20 candidates for infectious diseases and cancers from multiple groups. This is a new technology and, as yet, there are no licensed products.

Will mRNA vaccine produce better protection against the virus than vaccines developed through the conventional route?

We do not know yet what will work and how well, which is why multiple approaches are being taken for vaccine development.

How long will it take before we have a vaccine for commercial use?

It will take at least a year, if not longer.

This article is closed for comments.
Please Email the Editor

Printable version | Apr 17, 2021 5:58:25 PM |

In This Package
The Hindu Explains | How is India preparing to roll out COVID-19 vaccines?
The Hindu Explains | Why was a COVID-19 vaccine dry run necessary, and how was it organised?
Coronavirus | Why people with prior infection still need COVID-19 vaccination
Explained | What we know about China-made vaccines
How infections among participants are a part of vaccine trials | The Hindu In Focus podcast
The Hindu Explains | What is emergency use authorisation for drugs and vaccines?
Coronavirus | How the new variant quickly accumulated 23 mutations
Coronavirus | New variant does not increase reinfection risk, disease severity, deaths
Coronavirus | N501Y mutation in SARS-CoV-2 virus causes increased infectivity in mice: researchers
The Hindu Explains | Are viruses expected to change form, and will vaccines protect against a mutating SARS-CoV-2?
Coronavirus | Is the first wave coming to an end in India?
Has India passed the COVID-19 peak? | The Hindu Parley podcast
Has India passed its COVID-19 peak, as a new government study claims? | The Hindu In Focus podcast
No evidence to suggest coronavirus cluster 5 variant found in minks increases virus transmissibility, disease severity
SARS-CoV-2 not the last virus to spark a pandemic, says expert
The Hindu Explains | Who are the top contenders in the race for a COVID-19 vaccine?
The vaccine networks India will rely on and the challenges ahead | The Hindu In Focus podcast
Study advances use of indomethacin for treatment of mild cases
How an asymptomatic player turned super-spreader
How close are we to getting a COVID-19 vaccine? | The Hindu In Focus podcast
WHO warns against pursuing herd immunity to stop coronavirus
Studies document in-flight transmission of coronavirus
Experimental study finds how coronavirus can spread while speaking
Can universal masking be a crude ‘vaccine’?
The Hindu Explains | Is COVID-19 setting off a bradykinin storm in the body?
Coronavirus | Lung damage in COVID-19 dead may shed light on ‘long COVID’: study
The Hindu Explains | What does herd immunity mean for COVID-19?
The Hindu Explains | What do we know about Russia’s COVID-19 vaccine candidate Sputnik V?
Coronavirus | Russian vaccine generated strong immune response, says Lancet study
Watch | Is COVID-19 intensifying in rural India?
The Hindu Explains | Why is Phase-3 of COVID-19 vaccine trial complicated?
The Hindu Explains | What are the long-term effects of COVID-19?
The Hindu Explains | Are there re-infection fears around COVID-19?
Watch | COVID-19 and children
The Hindu Explains | Is SARS-CoV-2 a latent virus which can recur?
Watch | What is an immunity passport?
WHO says COVID-19 by far its worst global health emergency
CDC says revised guidance on coronavirus spread posted in error, removes it
Coronavirus | Plasma therapy may look promising in treating COVID-19, but it is no magic bullet
Coronavirus | Different kinds of SARS-CoV-2 exist in India but none more lethal than the other: Indian Academy of Sciences President
The Hindu Explains | Is airborne transmission of COVID-19 a risk?
Watch | What are serological surveys?
The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients?
Video: In conversation with Andrew Pollard, Director of Oxford Vaccine Group
Watch | All you need to know about pulse oximeters
Coronavirus | Why are only a fraction of cases tested?
You are reading
Coronavirus | Vaccine was rapidly synthesised as novel coronavirus sequence was available, says virologist Gagandeep Kang
A step closer to developing a potent drug against novel coronavirus
Coronavirus | The importance of ‘contact tracing’
Coronavirus | Are diabetics more prone to COVID-19?
Private firms ready to test for COVID-19
Coronavirus | How does soap use help in tackling COVID-19?
Fight for the finite: On budgetary allocation for health
Coronavirus | A problematic testing strategy
Fighting COVID-19 together for a shared future
Scientists get ready to test rival COVID-19 pandemic vaccines in animals
Coronavirus | The cost of opacity
Watch | COVID-19: Masks and sanitisers are now essential commodities
A COVID-19 control plan made simple
Watch | Your COVID-19 queries answered
Coronavirus | How is India containing COVID-19?
Battle against COVID-19
Watch | COVID-19: Dos and don'ts from the Health Ministry
A COVID-19 response that is quick off the blocks
Watch | Why is COVID-19 not a pandemic yet?
Watch | Coronavirus: Can masks protect you?
Watch | How is India dealing with coronavirus?
WHO’s unexplained hesitancy
Watch | Bats and the novel coronavirus
Coronavirus | India shares two SARS-CoV-2 genome sequences
COVID-19 | We are in uncharted territory, says WHO
Explained | Why is COVID-19 not a pandemic yet?
New COVID-19 epidemic at ‘decisive point’: WHO chief
COVID-19 vaccine may be ready by 2022: SII
Explainer: How WHO names a new disease
WHO names deadly viral disease from China as 'COVID-19'
Explained | When can people transmit the novel coronavirus?
Analysis | For China’s Xi, the coronavirus challenge comes laden with economic costs and political risks
How bats harbour several viruses yet not get sick
WHO declares coronavirus outbreak a global emergency
Watch | What is Coronavirus?
What is the source of the new SARS-like disease reported in China?
Data | The wide, rapid spread of the novel coronavirus
Alarming spread: on novel coronavirus outbreak
Gaps in our knowledge of coronavirus origin need fulfilment: Study
A new virus emerges in China
Next Story